<p>美國銀行（Bank of America Corp DE）在最近向證券交易委員會提交的文件中表示，在第四季度減少了對 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）的持股比例，降幅為 44.8%。該公司在出售了 181,848 股後，現持有 224,311 股生物技術公司的股票。截至最近的 SEC 文件，美國銀行持有 Rocket Pharmaceuticals 0.25% 的股份，價值 2,820,000 美元。</p>
<p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
<p>其他機構投資者和對沖基金也調整了對該公司的持股。Jennison Associates LLC 在第四季度將其在 Rocket Pharmaceuticals 的股份增加了 72.6%。Jennison Associates LLC 現在持有 70,304 股生物技術公司的股票，價值 884,000 美元，此前在上個季度購買了 29,564 股。Sovran Advisors LLC 在第四季度購買了 Rocket Pharmaceuticals 的新頭寸，價值約為 1,895,000 美元。Raymond James Financial Inc.在第四季度購買了 Rocket Pharmaceuticals 的新頭寸，價值約為 285,000 美元。Strategic Financial Concepts LLC 在第四季度購買了 Rocket Pharmaceuticals 的新股份，價值約為 141,000 美元。最後，Charles Schwab Investment Management Inc.在第四季度將其在 Rocket Pharmaceuticals 的股份增加了 15.1%。Charles Schwab Investment Management Inc.現在持有 656,090 股生物技術公司的股票，價值 8,247,000 美元，此前在上個季度購買了 86,276 股。機構投資者和對沖基金持有該公司 98.39% 的股份。</p>
<h2>Rocket Pharmaceuticals 股價下跌 5.3%</h2>
<p>RCKT 的股票在週五開盤價為 2.48 美元。該公司的債務與股本比率為 0.06，流動比率為 6.05，速動比率為 6.05。該公司的 50 日簡單移動平均為 6.20 美元，200 日簡單移動平均為 9.45 美元。Rocket Pharmaceuticals, Inc.的 1 年最低價為 2.19 美元，1 年最高價為 26.98 美元。該股票的市值為 2.6483 億美元，市盈率為-0.90，貝塔值為 1.02。</p>
<p>Rocket Pharmaceuticals（NASDAQ:RCKT - 獲取免費報告）最近於 5 月 13 日發佈了其財報。該生物技術公司報告第四季度每股收益（EPS）為（$0.56），超出市場共識預期的（$0.58）$0.02。在去年同期，該公司每股收益為（$0.66）。股票分析師預測 Rocket Pharmaceuticals, Inc.在當前財政年度將發佈-2.83 的每股收益。</p>
<h2>內部交易活動</h2>
<p>在相關消息中，首席執行官 Gaurav Shah 於 4 月 10 日星期四購買了 20,000 股公司的股票。該股票的平均購買價格為每股 5.08 美元，總價值為 101,600.00 美元。交易完成後，首席執行官現在持有 792,680 股公司的股票，價值約為 4,026,814.40 美元。這筆交易代表了其持股比例的 2.59% 的增加。該收購在 SEC 的文件中披露，可以通過此鏈接訪問。此外，首席財務官 Aaron Ondrey 於 4 月 4 日星期五出售了 7,489 股公司的股票。該股票的平均售價為 5.29 美元，總交易額為 39,616.81 美元。交易完成後，首席財務官現在直接持有 129,650 股公司的股票，價值 685,848.50 美元。這筆交易是其持股比例的 5.46% 的減少。該銷售的披露信息可以在這裏找到。公司內部人士持有該公司 24.76% 的股份。</p>
<h2>分析師設定新目標價</h2>
<p>多家研究公司最近對 RCKT 發佈了報告。BMO 資本市場將 Rocket Pharmaceuticals 的目標價從 30.00 美元下調至 8.00 美元，並在週三的研究報告中對該公司給予了 “跑贏大盤” 的評級。Wedbush 重申了 “跑贏大盤” 的評級，並在 5 月 16 日星期五的研究報告中對 Rocket Pharmaceuticals 的股票設定了 32.00 美元的目標價。高盛集團在週三的報告中將 Rocket Pharmaceuticals 的評級從 “中性” 下調至 “賣出”。Canaccord Genuity Group 在 5 月 12 日星期一的報告中將 Rocket Pharmaceuticals 的目標價從 36.00 美元下調至 34.00 美元，並對該股票給予了 “買入” 評級。最後，摩根士丹利在週三的研究報告中重申了 “持平” 的評級，並對 Rocket Pharmaceuticals 的股票設定了 7.00 美元的目標價。一位投資分析師對該股票給予了 “賣出” 評級，八位分析師給予了 “持有” 評級，九位分析師對該公司的股票給予了 “買入” 評級。根據 MarketBeat 的數據，Rocket Pharmaceuticals 目前的共識評級為 “持有”，共識目標價為 21.21 美元。</p>
<p><strong>獲取我們最新的 RCKT 股票分析</strong></p>
<h2>關於 Rocket Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Rocket Pharmaceuticals, Inc 及其子公司作為一家晚期生物技術公司，專注於開發針對罕見和嚴重疾病的基因療法。它有三個臨牀階段的外源性慢病毒載體項目，分別針對範可尼貧血（Fanconi anemia）、白細胞粘附缺陷-I（leukocyte adhesion deficiency-I）和丙酮酸激酶缺乏症（pyruvate kinase deficiency）。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Rocket Pharmaceuticals</li>
<li>如何投資藍籌股</li>
<li>接近 52 周低點，這 3 只中型股值得關注</li>
<li>外匯是什麼，如何運作？</li>
<li>3 個被忽視的股息投資機會，適合波動時期</li>
<li>TSX 風險投資交易所（前身為加拿大風險投資交易所）</li>
<li>AXON：競爭加劇，摩托羅拉以 44 億美元收購</li>
</ul>
<p><strong>想知道其他對 RCKT 持有倉位的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Rocket Pharmaceuticals 嗎？</h2>
<p>在考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rocket Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

美國銀行

Rocket制藥

<p>美國銀行（Bank of America Corp DE）在第四季度減少了對 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT）44.8% 的持股，目前持有 224,311 股，價值 282 萬美元。其他機構投資者也調整了他們的持倉。RCKT 的股價下跌 5.3%，至 2.48 美元，市值為 2.6483 億美元。該公司報告的季度每股收益為（0.56 美元），超出預期。分析師的目標價格各不相同，BMO 將其下調至 8.00 美元，而 Wedbush 維持在 32.00 美元。內部交易方面，首席執行官 Gaurav Shah 購買了 20,000 股</p>

<p>Bank of America Corp DE lessened its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 44.8% in the 4th quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm owned 224,311 shares of the biotechnology company's stock after selling 181,848 shares during the quarter. Bank of America Corp DE owned 0.25% of Rocket Pharmaceuticals worth $2,820,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>美國銀行（Bank of America Corp DE）在最近向證券交易委員會提交的文件中表示，在第四季度減少了對 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）的持股比例，降幅為 44.8%。該公司在出售了 181,848 股後，現持有 224,311 股生物技術公司的股票。截至最近的 SEC 文件，美國銀行持有 Rocket Pharmaceuticals 0.25% 的股份，價值 2,820,000 美元。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
</div><p>Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Rocket Pharmaceuticals by 72.6% in the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company's stock valued at $884,000 after purchasing an additional 29,564 shares in the last quarter. Sovran Advisors LLC purchased a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $1,895,000. Raymond James Financial Inc. purchased a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $285,000. Strategic Financial Concepts LLC purchased a new stake in Rocket Pharmaceuticals during the 4th quarter worth approximately $141,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Rocket Pharmaceuticals by 15.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 656,090 shares of the biotechnology company's stock worth $8,247,000 after buying an additional 86,276 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也調整了對該公司的持股。Jennison Associates LLC 在第四季度將其在 Rocket Pharmaceuticals 的股份增加了 72.6%。Jennison Associates LLC 現在持有 70,304 股生物技術公司的股票，價值 884,000 美元，此前在上個季度購買了 29,564 股。Sovran Advisors LLC 在第四季度購買了 Rocket Pharmaceuticals 的新頭寸，價值約為 1,895,000 美元。Raymond James Financial Inc.在第四季度購買了 Rocket Pharmaceuticals 的新頭寸，價值約為 285,000 美元。Strategic Financial Concepts LLC 在第四季度購買了 Rocket Pharmaceuticals 的新股份，價值約為 141,000 美元。最後，Charles Schwab Investment Management Inc.在第四季度將其在 Rocket Pharmaceuticals 的股份增加了 15.1%。Charles Schwab Investment Management Inc.現在持有 656,090 股生物技術公司的股票，價值 8,247,000 美元，此前在上個季度購買了 86,276 股。機構投資者和對沖基金持有該公司 98.39% 的股份。</p>
</div><h2>Rocket Pharmaceuticals Trading Down 5.3%</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股價下跌 5.3%</h2>
</div><p>Shares of RCKT opened at $2.48 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The firm has a 50 day simple moving average of $6.20 and a 200-day simple moving average of $9.45. Rocket Pharmaceuticals, Inc. has a 1-year low of $2.19 and a 1-year high of $26.98. The stock has a market cap of $264.83 million, a price-to-earnings ratio of -0.90 and a beta of 1.02.</p>
<div class="lb-trans"><p>RCKT 的股票在週五開盤價為 2.48 美元。該公司的債務與股本比率為 0.06，流動比率為 6.05，速動比率為 6.05。該公司的 50 日簡單移動平均為 6.20 美元，200 日簡單移動平均為 9.45 美元。Rocket Pharmaceuticals, Inc.的 1 年最低價為 2.19 美元，1 年最高價為 26.98 美元。該股票的市值為 2.6483 億美元，市盈率為-0.90，貝塔值為 1.02。</p>
</div><p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. Equities analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（NASDAQ:RCKT - 獲取免費報告）最近於 5 月 13 日發佈了其財報。該生物技術公司報告第四季度每股收益（EPS）為（$0.56），超出市場共識預期的（$0.58）$0.02。在去年同期，該公司每股收益為（$0.66）。股票分析師預測 Rocket Pharmaceuticals, Inc.在當前財政年度將發佈-2.83 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In related news, CEO Gaurav Shah bought 20,000 shares of the company's stock in a transaction dated Thursday, April 10th. The stock was bought at an average price of $5.08 per share, with a total value of $101,600.00. Following the transaction, the chief executive officer now owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. This trade represents a 2.59% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Aaron Ondrey sold 7,489 shares of the business's stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the completion of the sale, the chief financial officer now directly owns 129,650 shares of the company's stock, valued at $685,848.50. The trade was a 5.46% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 24.76% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席執行官 Gaurav Shah 於 4 月 10 日星期四購買了 20,000 股公司的股票。該股票的平均購買價格為每股 5.08 美元，總價值為 101,600.00 美元。交易完成後，首席執行官現在持有 792,680 股公司的股票，價值約為 4,026,814.40 美元。這筆交易代表了其持股比例的 2.59% 的增加。該收購在 SEC 的文件中披露，可以通過此鏈接訪問。此外，首席財務官 Aaron Ondrey 於 4 月 4 日星期五出售了 7,489 股公司的股票。該股票的平均售價為 5.29 美元，總交易額為 39,616.81 美元。交易完成後，首席財務官現在直接持有 129,650 股公司的股票，價值 685,848.50 美元。這筆交易是其持股比例的 5.46% 的減少。該銷售的披露信息可以在這裏找到。公司內部人士持有該公司 24.76% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research firms have recently issued reports on RCKT. BMO Capital Markets dropped their price target on Rocket Pharmaceuticals from $30.00 to $8.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Wedbush reiterated an &#34;outperform&#34; rating and issued a $32.00 price objective on shares of Rocket Pharmaceuticals in a research note on Friday, May 16th. The Goldman Sachs Group lowered Rocket Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;sell&#34; rating in a report on Wednesday. Canaccord Genuity Group dropped their price objective on Rocket Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, May 12th. Finally, Morgan Stanley reiterated an &#34;equal weight&#34; rating and set a $7.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $21.21.</p>
<div class="lb-trans"><p>多家研究公司最近對 RCKT 發佈了報告。BMO 資本市場將 Rocket Pharmaceuticals 的目標價從 30.00 美元下調至 8.00 美元，並在週三的研究報告中對該公司給予了 “跑贏大盤” 的評級。Wedbush 重申了 “跑贏大盤” 的評級，並在 5 月 16 日星期五的研究報告中對 Rocket Pharmaceuticals 的股票設定了 32.00 美元的目標價。高盛集團在週三的報告中將 Rocket Pharmaceuticals 的評級從 “中性” 下調至 “賣出”。Canaccord Genuity Group 在 5 月 12 日星期一的報告中將 Rocket Pharmaceuticals 的目標價從 36.00 美元下調至 34.00 美元，並對該股票給予了 “買入” 評級。最後，摩根士丹利在週三的研究報告中重申了 “持平” 的評級，並對 Rocket Pharmaceuticals 的股票設定了 7.00 美元的目標價。一位投資分析師對該股票給予了 “賣出” 評級，八位分析師給予了 “持有” 評級，九位分析師對該公司的股票給予了 “買入” 評級。根據 MarketBeat 的數據，Rocket Pharmaceuticals 目前的共識評級為 “持有”，共識目標價為 21.21 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on RCKT</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 RCKT 股票分析</strong></p>
</div><h2>About Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Rocket Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 及其子公司作為一家晚期生物技術公司，專注於開發針對罕見和嚴重疾病的基因療法。它有三個臨牀階段的外源性慢病毒載體項目，分別針對範可尼貧血（Fanconi anemia）、白細胞粘附缺陷-I（leukocyte adhesion deficiency-I）和丙酮酸激酶缺乏症（pyruvate kinase deficiency）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look</li>
<li>What is Forex and How Does it Work?</li>
<li>3 Overlooked Dividend Plays for Income in Volatile Times</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Rocket Pharmaceuticals</li>
<li>如何投資藍籌股</li>
<li>接近 52 周低點，這 3 只中型股值得關注</li>
<li>外匯是什麼，如何運作？</li>
<li>3 個被忽視的股息投資機會，適合波動時期</li>
<li>TSX 風險投資交易所（前身為加拿大風險投資交易所）</li>
<li>AXON：競爭加劇，摩托羅拉以 44 億美元收購</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RCKT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 RCKT 持有倉位的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Rocket Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rocket Pharmaceuticals 並不在名單上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bank of America Corp DE

- 美國銀行在第四季度減少了對 Rocket Pharmaceuticals 的持股 44.8%。  
- 該公司目前持有 224,311 股，市值約 282 萬美元。  
- 機構投資者和對沖基金持有該公司 98.39% 的股份。  

美國銀行公司 DE 出售了 Rocket Pharmaceuticals, Inc.（納斯達克股票代碼：RCKT）的股份